KRT10 and Olmsted syndrome: Although the localization of keratin 10 and keratin 14 indicated defects in maturation, MuPVLP-shRNA treatment resulted in thinner epidermis, 55.6 ± 8.0 μm SD, which was significantly lower than untreated DS-Nh (Figure 8D), suggesting a mitigation of the hyperkeratosis associated with Olmsted syndrome phenotype.